Performed on formalin-fixed, surgically resected breast cancer tissue, the test serves to classify a tumor into one of four subtypes (luminal A, luminal B, HER2-enriched, and basal-like), which have been shown to have prognostic value in both untreated and treated patients (Nielsen et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.